KalVista Pharmaceuticals (United States)

Recent papers from KalVista Pharmaceuticals (United States)

1. Turbulent Heat Transfer in Lattice-Structured Matrix Cooling ChannelsJournal of Turbomachinery · 2026
2. Numerical Investigation of Turbulent Heat Transfer Over Rough Surfaces at Medium–high Prandtl NumbersJournal of Turbomachinery · 2026
3. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-SJournal of Allergy and Clinical Immunology Global · 2026
4. Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsWorld Allergy Organization Journal · 2026
5. Long-term prophylaxis in hereditary angioedema: Real-world treatment patterns and healthcare resource utilizationWorld Allergy Organization Journal · 2026
6. Feasibility of a heart failure management programme using Remote Dielectric Sensing technology for the non-invasive lung fluid monitoring in primary care: A mixed-methods studyEuropean Journal of Cardiovascular Nursing · 2026
7. Evaluation of organic versus synthetic derived Multivitamin and Mineral supplementation on circulatory concentration in healthy humans; A Single-blinded Randomized Intervention StudyCurrent Developments in Nutrition · 2026
8. Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.2026
9. Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐SClinical and Translational Allergy · 2025
10. A sensitive and specific assay to characterize plasma kallikrein activity in plasma from patients with hereditary angioedemaWorld Allergy Organization Journal · 2025
11. Impact of hereditary angioedema attacks on health-related quality of life and work productivityWorld Allergy Organization Journal · 2025
12. The kallikrein kinin system alters neuroretinal and visual responses in miceExperimental Eye Research · 2025
13. Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedemaAllergy Asthma and Clinical Immunology · 2025
14. Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacksAllergy Asthma and Clinical Immunology · 2025
15. Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitorJournal of Allergy and Clinical Immunology Global · 2025
16. Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelinesJournal of Allergy and Clinical Immunology · 2024
17. Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 ratsAJP Renal Physiology · 2024
18. On-demand treatment of hereditary angioedema attacksAnnals of Allergy Asthma & Immunology · 2024
19. Management of hereditary angioedema attacks by patients on long-term prophylaxis versus on-demand therapy onlyAllergy and Asthma Proceedings · 2024
20. Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic ReviewClinical Reviews in Allergy & Immunology · 2024